table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2022-2027)
1.4.2 East Asia Market States and Outlook (2022-2027)
1.4.3 Europe Market States and Outlook (2022-2027)
1.4.4 South Asia Market States and Outlook (2022-2027)
1.4.5 Southeast Asia Market States and Outlook (2022-2027)
1.4.6 Middle East Market States and Outlook (2022-2027)
1.4.7 Africa Market States and Outlook (2022-2027)
1.4.8 Oceania Market States and Outlook (2022-2027)
1.4.9 South America Market States and Outlook (2022-2027)
1.5 Global Anti-Obesity Prescription Drugs Market Size Analysis from 2022 to 2027
1.5.1 Global Anti-Obesity Prescription Drugs Market Size Analysis from 2022 to 2027 by Consumption Volume
1.5.2 Global Anti-Obesity Prescription Drugs Market Size Analysis from 2022 to 2027 by Value
1.5.3 Global Anti-Obesity Prescription Drugs Price Trends Analysis from 2022 to 2027
1.6 COVID-19 Outbreak: Anti-Obesity Prescription Drugs Industry Impact
Chapter 2 Global Anti-Obesity Prescription Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Anti-Obesity Prescription Drugs (Volume and Value) by Type
2.1.1 Global Anti-Obesity Prescription Drugs Consumption and Market Share by Type (2016-2021)
2.1.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2016-2021)
2.2 Global Anti-Obesity Prescription Drugs (Volume and Value) by Application
2.2.1 Global Anti-Obesity Prescription Drugs Consumption and Market Share by Application (2016-2021)
2.2.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Application (2016-2021)
2.3 Global Anti-Obesity Prescription Drugs (Volume and Value) by Regions
2.3.1 Global Anti-Obesity Prescription Drugs Consumption and Market Share by Regions (2016-2021)
2.3.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Regions (2016-2021)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2016-2021 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2016-2021 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2016-2021 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import by Regions (2016-2021)
4.1 Global Anti-Obesity Prescription Drugs Consumption by Regions (2016-2021)
4.2 North America Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.3 East Asia Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.4 Europe Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.5 South Asia Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.6 Southeast Asia Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.7 Middle East Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.8 Africa Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.9 Oceania Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
4.10 South America Anti-Obesity Prescription Drugs Sales, Consumption, Export, Import (2016-2021)
Chapter 5 North America Anti-Obesity Prescription Drugs Market Analysis
5.1 North America Anti-Obesity Prescription Drugs Consumption and Value Analysis
5.1.1 North America Anti-Obesity Prescription Drugs Market Under COVID-19
5.2 North America Anti-Obesity Prescription Drugs Consumption Volume by Types
5.3 North America Anti-Obesity Prescription Drugs Consumption Structure by Application
5.4 North America Anti-Obesity Prescription Drugs Consumption by Top Countries
5.4.1 United States Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
5.4.2 Canada Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
5.4.3 Mexico Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 6 East Asia Anti-Obesity Prescription Drugs Market Analysis
6.1 East Asia Anti-Obesity Prescription Drugs Consumption and Value Analysis
6.1.1 East Asia Anti-Obesity Prescription Drugs Market Under COVID-19
6.2 East Asia Anti-Obesity Prescription Drugs Consumption Volume by Types
6.3 East Asia Anti-Obesity Prescription Drugs Consumption Structure by Application
6.4 East Asia Anti-Obesity Prescription Drugs Consumption by Top Countries
6.4.1 China Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
6.4.2 Japan Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
6.4.3 South Korea Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 7 Europe Anti-Obesity Prescription Drugs Market Analysis
7.1 Europe Anti-Obesity Prescription Drugs Consumption and Value Analysis
7.1.1 Europe Anti-Obesity Prescription Drugs Market Under COVID-19
7.2 Europe Anti-Obesity Prescription Drugs Consumption Volume by Types
7.3 Europe Anti-Obesity Prescription Drugs Consumption Structure by Application
7.4 Europe Anti-Obesity Prescription Drugs Consumption by Top Countries
7.4.1 Germany Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.2 UK Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.3 France Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.4 Italy Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.5 Russia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.6 Spain Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.7 Netherlands Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.8 Switzerland Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
7.4.9 Poland Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 8 South Asia Anti-Obesity Prescription Drugs Market Analysis
8.1 South Asia Anti-Obesity Prescription Drugs Consumption and Value Analysis
8.1.1 South Asia Anti-Obesity Prescription Drugs Market Under COVID-19
8.2 South Asia Anti-Obesity Prescription Drugs Consumption Volume by Types
8.3 South Asia Anti-Obesity Prescription Drugs Consumption Structure by Application
8.4 South Asia Anti-Obesity Prescription Drugs Consumption by Top Countries
8.4.1 India Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
8.4.2 Pakistan Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
8.4.3 Bangladesh Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 9 Southeast Asia Anti-Obesity Prescription Drugs Market Analysis
9.1 Southeast Asia Anti-Obesity Prescription Drugs Consumption and Value Analysis
9.1.1 Southeast Asia Anti-Obesity Prescription Drugs Market Under COVID-19
9.2 Southeast Asia Anti-Obesity Prescription Drugs Consumption Volume by Types
9.3 Southeast Asia Anti-Obesity Prescription Drugs Consumption Structure by Application
9.4 Southeast Asia Anti-Obesity Prescription Drugs Consumption by Top Countries
9.4.1 Indonesia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.2 Thailand Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.3 Singapore Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.4 Malaysia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.5 Philippines Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.6 Vietnam Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
9.4.7 Myanmar Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 10 Middle East Anti-Obesity Prescription Drugs Market Analysis
10.1 Middle East Anti-Obesity Prescription Drugs Consumption and Value Analysis
10.1.1 Middle East Anti-Obesity Prescription Drugs Market Under COVID-19
10.2 Middle East Anti-Obesity Prescription Drugs Consumption Volume by Types
10.3 Middle East Anti-Obesity Prescription Drugs Consumption Structure by Application
10.4 Middle East Anti-Obesity Prescription Drugs Consumption by Top Countries
10.4.1 Turkey Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.2 Saudi Arabia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.3 Iran Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.4 United Arab Emirates Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.5 Israel Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.6 Iraq Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.7 Qatar Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.8 Kuwait Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
10.4.9 Oman Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 11 Africa Anti-Obesity Prescription Drugs Market Analysis
11.1 Africa Anti-Obesity Prescription Drugs Consumption and Value Analysis
11.1.1 Africa Anti-Obesity Prescription Drugs Market Under COVID-19
11.2 Africa Anti-Obesity Prescription Drugs Consumption Volume by Types
11.3 Africa Anti-Obesity Prescription Drugs Consumption Structure by Application
11.4 Africa Anti-Obesity Prescription Drugs Consumption by Top Countries
11.4.1 Nigeria Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
11.4.2 South Africa Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
11.4.3 Egypt Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
11.4.4 Algeria Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
11.4.5 Morocco Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 12 Oceania Anti-Obesity Prescription Drugs Market Analysis
12.1 Oceania Anti-Obesity Prescription Drugs Consumption and Value Analysis
12.2 Oceania Anti-Obesity Prescription Drugs Consumption Volume by Types
12.3 Oceania Anti-Obesity Prescription Drugs Consumption Structure by Application
12.4 Oceania Anti-Obesity Prescription Drugs Consumption by Top Countries
12.4.1 Australia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
12.4.2 New Zealand Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 13 South America Anti-Obesity Prescription Drugs Market Analysis
13.1 South America Anti-Obesity Prescription Drugs Consumption and Value Analysis
13.1.1 South America Anti-Obesity Prescription Drugs Market Under COVID-19
13.2 South America Anti-Obesity Prescription Drugs Consumption Volume by Types
13.3 South America Anti-Obesity Prescription Drugs Consumption Structure by Application
13.4 South America Anti-Obesity Prescription Drugs Consumption Volume by Major Countries
13.4.1 Brazil Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.2 Argentina Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.3 Columbia Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.4 Chile Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.5 Venezuela Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.6 Peru Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.7 Puerto Rico Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
13.4.8 Ecuador Anti-Obesity Prescription Drugs Consumption Volume from 2016 to 2021
Chapter 14 Company Profiles and Key Figures in Anti-Obesity Prescription Drugs Business
14.1 F Hoffmann La Roche Ltd
14.1.1 F Hoffmann La Roche Ltd Company Profile
14.1.2 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Product Specification
14.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.2 Orexigen Therapeutics
14.2.1 Orexigen Therapeutics Company Profile
14.2.2 Orexigen Therapeutics Anti-Obesity Prescription Drugs Product Specification
14.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.3 Novo Nordisk A/s
14.3.1 Novo Nordisk A/s Company Profile
14.3.2 Novo Nordisk A/s Anti-Obesity Prescription Drugs Product Specification
14.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.4 Arena Pharmaceuticals
14.4.1 Arena Pharmaceuticals Company Profile
14.4.2 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Product Specification
14.4.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.5 Glaxosmithkline
14.5.1 Glaxosmithkline Company Profile
14.5.2 Glaxosmithkline Anti-Obesity Prescription Drugs Product Specification
14.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.6 Vivus
14.6.1 Vivus Company Profile
14.6.2 Vivus Anti-Obesity Prescription Drugs Product Specification
14.6.3 Vivus Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.7 Boehringer Ingelheim
14.7.1 Boehringer Ingelheim Company Profile
14.7.2 Boehringer Ingelheim Anti-Obesity Prescription Drugs Product Specification
14.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
14.8 Alizyme
14.8.1 Alizyme Company Profile
14.8.2 Alizyme Anti-Obesity Prescription Drugs Product Specification
14.8.3 Alizyme Anti-Obesity Prescription Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
Chapter 15 Global Anti-Obesity Prescription Drugs Market Forecast (2022-2027)
15.1 Global Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Price Forecast (2022-2027)
15.1.1 Global Anti-Obesity Prescription Drugs Consumption Volume and Growth Rate Forecast (2022-2027)
15.1.2 Global Anti-Obesity Prescription Drugs Value and Growth Rate Forecast (2022-2027)
15.2 Global Anti-Obesity Prescription Drugs Consumption Volume, Value and Growth Rate Forecast by Region (2022-2027)
15.2.1 Global Anti-Obesity Prescription Drugs Consumption Volume and Growth Rate Forecast by Regions (2022-2027)
15.2.2 Global Anti-Obesity Prescription Drugs Value and Growth Rate Forecast by Regions (2022-2027)
15.2.3 North America Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.4 East Asia Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.5 Europe Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.6 South Asia Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.7 Southeast Asia Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.8 Middle East Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.9 Africa Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.10 Oceania Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.2.11 South America Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Growth Rate Forecast (2022-2027)
15.3 Global Anti-Obesity Prescription Drugs Consumption Volume, Revenue and Price Forecast by Type (2022-2027)
15.3.1 Global Anti-Obesity Prescription Drugs Consumption Forecast by Type (2022-2027)
15.3.2 Global Anti-Obesity Prescription Drugs Revenue Forecast by Type (2022-2027)
15.3.3 Global Anti-Obesity Prescription Drugs Price Forecast by Type (2022-2027)
15.4 Global Anti-Obesity Prescription Drugs Consumption Volume Forecast by Application (2022-2027)
15.5 Anti-Obesity Prescription Drugs Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology
